Sc
Sciwind Bio
Shanghai CNFounded 2011200 employees
Private CapbiotechPrivateMetabolic
Platform: GLP-1 Obesity
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| SCI-9093 | SCI-9093 | Phase 1/2 | 2 | CD20 | GIST | ||
| Ribotinib | SCI-9914 | Phase 1/2 | 1 | CD20 | CFMeso | ||
| Surasacituzumab | SCI-4225 | Phase 3 | 3 | AuroraA | SCDCLL | ||
| SCI-8054 | SCI-8054 | Phase 2/3 | 1 | PRMT5 | Ewing SarcomaHuntington's |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)